Lecithin-chitosan-TPGS nanoparticles as nanocarriers of (-)-epicatechin enhanced its anticancer activity in breast cancer cells

Adriana Guadalupe Perez-Ruiz, Adriana Ganem, Ivonne María Olivares-Corichi, José Rubén García-Sánchez

    Research output: Contribution to journalArticle

    1 Scopus citations

    Abstract

    Natural compounds such as (-)-epicatechin show a variety of biological properties including anticancer activity. Nonetheless, (-)-epicatechin's therapeutic application is limited due to its low water solubility and sensitivity to oxygen and light. Additionally, previous studies have reported that the encapsulation of flavonoids in nanoparticles might generate stable deliverable forms, which improves the availability and solubility of the bioactive compounds. The aims of this study were to generate (-)-epicatechin-loaded lecithin-chitosan nanoparticles (EC-LCT-NPs) by molecular self-assembly and to assess their cytotoxic potential against breast cancer cells. Various parameters were measured to characterize the EC-LCT-NPs including size, polydispersity index (PdI), zeta potential, morphology and entrapment efficiency. The results showed that the mean particle size of the EC-CLT-NPs was 159 ± 2.23 nm (PdI, 0.189), and the loading and entrapment efficiencies of (-)-epicatechin were 3.42 ± 0.85% and 56.1 ± 3.9%, respectively. The cytotoxic effect of the EC-CLT-NPs was greater than that of free (-)-epicatechin on breast cancer cell lines (MCF-7, MDA-MB-231, MDA-MB-436 and SK-Br3). Indeed, EC-LCT-NPs showed an IC50 that was four-fold lower (85 μM) than free (-)-epicatechin (350 μM) and showed selectivity to cancerous cells. This study demonstrated that encapsulating (-)-epicatechin into lecithin-chitosan nanoparticles opens new options for breast cancer treatment.

    Original languageEnglish
    Pages (from-to)34773-34782
    Number of pages10
    JournalRSC Advances
    Volume8
    Issue number61
    DOIs
    StatePublished - 1 Jan 2018

      Fingerprint

    Cite this